Hadasit Bio-Holdings

Press Releases

report from D Pharm Company Ltd. – the results of a rights issue

Jan. 22, 2015

HBL – Hadasit Bio - Holdings Ltd.

(The Company)

 

January 21, 2015

 

To

The Israel Securities Authority

www.isa.gov.il

To

The Tel Aviv Stock Exchange Ltd.

www.tase.co.il

 

Re: A report from D Pharm Company Ltd. – the results of a rights issue

 

The company is pleased to inform that the D Pharm Company Ltd., a company traded on the Tel Aviv Stock Exchange (herein: D Pharm), has published today through an immediate report, the results of a rights issue according to an off the shelf report offer published by D Pharm on December 25, 2014 (ref no. 2014–01–231303) (herein: the rights issue).

 

According to the said D Pharm immediate report, the immediate gross proceeds received by D Pharm for the rights realized in the rights issue amount to be approximately 12,775 thousands NIS.

 

The D Pharm Company’s holdings rate after the rights issue is 5.57% (5.55% in full dilution).

 

For more information about the results of the rights issue, please see the immediate report form the D Pharm Company from today (ref no. 2015–01–015937).

 

With Regards,

 

HBL – Hadasit Bio - Holdings Ltd.

By: Ms. Tamar Kfir, CEO

 
 
 

Press Releases Archive